Drug Target Review
JUNE 16, 2025
DT-9046 is an orally delivered small molecule that has reached pre-IND studies – making Domain the first company to successfully advance a small molecule candidate targeting PAR2.
BioPharma Drive: Drug Pricing
JULY 8, 2025
Specially designed small molecule drugs can bring together target proteins with an enzyme that tags them with ubiquitin, thereby marking them for destruction. In their 2001 paper, Crews, Deshaies and others described how synthetic molecules could attach ubiquitins to unwanted cell parts. "It
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DrugBaron
JULY 19, 2022
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
DrugBaron
FEBRUARY 7, 2022
Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.
The Pharma Data
SEPTEMBER 22, 2020
Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). Activated NLRP3 is involved in the production of pro-inflammatory cytokines IL-1?
DrugBaron
JANUARY 31, 2024
Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.
Dark Matter Blog
JUNE 21, 2023
Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.
Expert insights. Personalized for you.
59 
Let's personalize your content